Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments

AbstractThere is a distinct need for new and second-line therapies to delay or prevent local tumor regrowth after current standard of care therapy. Intracavitary radioimmunotherapy, in combination with radiotherapy, is discussed in the present review as a therapeutic strategy of high potential. We performed a systematic literature search following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). The available body of literature on intracavitary radioimmunotherapy (iRIT) in glioblastoma and anaplastic astrocytomas is presented. Several past and current phase I and II clinical trials, using mostly an anti-tenascin monoclonal antibody labeled with I-131, have shown median overall survival of 19 –25 months in glioblastoma, while adverse events remain low. Tenascin, followed by EGFR and variants, or smaller peptides have been used as targets, and most clinical studies were performed with I-131 or Y-90 as radionuclides while only recently Re-188, I-125, and Bi-213 were applied. The pharmac okinetics of iRIT, as well as the challenges encountered with this therapy, is comprehensively discussed. This promising approach deserves further exploration in future studies by incorporating several innovative modifications.
Source: Acta Neurochirurgica - Category: Neurosurgery Source Type: research

Related Links:

Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This cIMPACT-NOW update was published this month:Summary:cIMPACT (Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) has reviewed the status of WHO grade II IDH-wt/H3-wt diffuse gliomas, focusing on those with a BRAFV600E mutation, FGFR1 alteration, or a MYB or MYBL1 rearrangement, and recommends the use of an integrated diagnosis to combine their histologic and genetic features. The consortium ecommends the use of an integrated diagnosis to combine their histologic and genetic features, as suggested in the following:Diffuse glioma, MYB...
Source: neuropathology blog - Category: Radiology Tags: molecular studies neoplasms Source Type: blogs
CONCLUSIONS: No increasing incidence trend was observed for malignant gliomas overall. An increasing incidence trend of malignant gliomas was found in the oldest age group during 1990-2006. PMID: 30985227 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Conclusion5-ALA could play a role in resection of pediatric brain tumors. However, further prospective clinical trials are needed.
Source: Acta Neurochirurgica - Category: Neurosurgery Source Type: research
Conclusion: The efficacy of brainstem gliomas—treated with CyberKnife is efficacious with mild toxicity. Introduction Brainstem gliomas (BSGs) account for 5–15% of brain tumors and more likely happen in children (1). BSGs constitute at least 20% of childhood brain neoplasms (2), and the peak age is 7–9 years. In contrast, BSGs is rare in the adult population and account for only 1.5–2.5% of brain glioma, with a peak age of 40–70 years (1). Diffuse intrinsic pontine glioma(DIPG) was the most common type of BSG is that could invade the whole brainstem including midbrain, pons as well as me...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, we have shown the safety and efficacy of Vemurafenib in a pediatric patient with DS affected by PXA. Ethics Statement This study was carried out in accordance with the recommendations of the Internal Review Board of the Bambino Gesù Children's Hospital with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Internal Review Board of the Bambino Gesù Children's Hospital. Informed Consent The authors declare that written informed consent was obtained from the pat...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We report four cases of high-grade astrocytoma with aBRAF V600E mutation,ATRX inactivation, andCDKN2A/B homozygous deletion. Children to young adults aged 3 –46 presented with a well demarcated contrast-enhancing mass in the supratentorial area. Pathological examination revealed packed growth of short spindle to round polygonal cells including some pleomorphic cells. The tumors had less ability to infiltrate into the adjacent brain parenchyma and pres ented a circumscribed growth pattern. Mitosis was readily found, accompanied by focal necrosis and/or microvascular proliferation. Tumors were histologically similar in...
Source: Brain Tumor Pathology - Category: Neurology Source Type: research
AbstractNeurofibromatosis 1 (NF1) is an autosomal dominant genetic disorder that presents with variable phenotypes as a result of mutations in the neurofibromatosis type 1 (NF1) gene and subsequently, abnormal function of the protein product, neurofibromin. Patients with NF1 are at increased risk for central nervous system (CNS) manifestations including structural, functional, and neoplastic disease. The mechanisms underlying the varied manifestations of NF1 are incompletely understood, but the loss of functional neurofibromin, resulting in sustained activation of the oncoprotein RAS, is responsible for tumorigenesis throu...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
Conditions:   Glioma;   Astrocytoma;   Oligodendroglioma;   Ependymoma;   Ganglioglioma;   Pleomorphic Xanthoastrocytoma Interventions:   Other: Part 1 Survey Group;   Other: Part 2 Focus Group Sponsor:   Wake Forest University Health Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   IDH1 wt Allele;   Recurrent Anaplastic Astrocytoma;   Recurrent Glioblastoma;   Recurrent Gliosarcoma;   Recurrent Malignant Glioma Interventions:   Biological: Oncolytic Adenovirus Ad5-DNX-2401;   Procedure: Therapeutic Conventional Surgery Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Astrocytoma | Brain | Brain Tumor | Clinical Trials | Glioma | Neurology | Neurosurgery | Study